Ambu Valuation

Is AMBU B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AMBU B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AMBU B (DKK134) is trading above our estimate of fair value (DKK75.93)

Significantly Below Fair Value: AMBU B is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMBU B?

Other financial metrics that can be useful for relative valuation.

AMBU B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.1x
Enterprise Value/EBITDA54.8x
PEG Ratio3.8x

Price to Earnings Ratio vs Peers

How does AMBU B's PE Ratio compare to its peers?

The above table shows the PE ratio for AMBU B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.9x
DEMANT Demant
25.7x12.4%DKK 65.6b
EMBLA Embla Medical hf
31.8x16.5%DKK 12.6b
COLO B Coloplast
37.9x12.5%DKK 188.1b
002223 Jiangsu Yuyue Medical Equipment & Supply
16.1x9.3%CN¥37.7b
97.2x25.6%DKK 35.7b

Price-To-Earnings vs Peers: AMBU B is expensive based on its Price-To-Earnings Ratio (97.2x) compared to the peer average (27.9x).


Price to Earnings Ratio vs Industry

How does AMBU B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: AMBU B is expensive based on its Price-To-Earnings Ratio (97.2x) compared to the European Medical Equipment industry average (30.3x).


Price to Earnings Ratio vs Fair Ratio

What is AMBU B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMBU B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio97.2x
Fair PE Ratio49.6x

Price-To-Earnings vs Fair Ratio: AMBU B is expensive based on its Price-To-Earnings Ratio (97.2x) compared to the estimated Fair Price-To-Earnings Ratio (49.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AMBU B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 134.00
DKK 113.80
-15.1%
25.0%DKK 138.00DKK 59.00n/a5
Jun ’25DKK 131.40
DKK 111.20
-15.4%
24.9%DKK 138.00DKK 59.00n/a5
May ’25DKK 111.95
DKK 107.20
-4.2%
26.4%DKK 130.00DKK 52.00n/a5
Apr ’25DKK 113.55
DKK 107.20
-5.6%
26.4%DKK 130.00DKK 52.00n/a5
Mar ’25DKK 121.45
DKK 107.20
-11.7%
26.4%DKK 130.00DKK 52.00n/a5
Feb ’25DKK 111.60
DKK 105.00
-5.9%
26.7%DKK 130.00DKK 52.00n/a5
Jan ’25DKK 105.20
DKK 85.67
-18.6%
26.2%DKK 115.00DKK 47.00n/a6
Dec ’24DKK 91.94
DKK 85.67
-6.8%
26.2%DKK 115.00DKK 47.00n/a6
Nov ’24DKK 69.86
DKK 89.40
+28.0%
28.2%DKK 120.00DKK 53.00n/a5
Oct ’24DKK 73.86
DKK 95.60
+29.4%
25.6%DKK 120.00DKK 53.00n/a5
Sep ’24DKK 83.56
DKK 96.00
+14.9%
25.3%DKK 120.00DKK 53.00n/a5
Aug ’24DKK 99.16
DKK 101.80
+2.7%
27.0%DKK 135.00DKK 59.00n/a5
Jul ’24DKK 111.65
DKK 102.60
-8.1%
26.9%DKK 135.00DKK 59.00n/a5
Jun ’24DKK 107.50
DKK 102.60
-4.6%
26.9%DKK 135.00DKK 59.00DKK 131.405
May ’24DKK 105.50
DKK 101.60
-3.7%
28.4%DKK 135.00DKK 55.00DKK 111.955
Apr ’24DKK 102.75
DKK 96.25
-6.3%
30.8%DKK 135.00DKK 55.00DKK 113.554
Mar ’24DKK 101.35
DKK 104.60
+3.2%
30.2%DKK 140.00DKK 55.00DKK 121.455
Feb ’24DKK 99.14
DKK 87.80
-11.4%
20.6%DKK 110.00DKK 65.00DKK 111.605
Jan ’24DKK 89.00
DKK 83.40
-6.3%
19.5%DKK 110.00DKK 65.00DKK 105.205
Dec ’23DKK 91.70
DKK 83.20
-9.3%
19.8%DKK 110.00DKK 64.00DKK 91.945
Nov ’23DKK 88.88
DKK 76.50
-13.9%
11.7%DKK 85.00DKK 64.00DKK 69.864
Oct ’23DKK 66.42
DKK 76.50
+15.2%
11.7%DKK 85.00DKK 64.00DKK 73.864
Sep ’23DKK 70.74
DKK 76.50
+8.1%
11.7%DKK 85.00DKK 64.00DKK 83.564
Aug ’23DKK 81.68
DKK 94.25
+15.4%
6.4%DKK 100.00DKK 86.00DKK 99.164
Jul ’23DKK 73.96
DKK 94.25
+27.4%
6.4%DKK 100.00DKK 86.00DKK 111.654
Jun ’23DKK 91.52
DKK 94.25
+3.0%
6.4%DKK 100.00DKK 86.00DKK 107.504

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.